Post-marketing oncology studies: Enabling faster recruitment and lower costs
Post-marketing approval studies in clinical research for cancer typically suffer from poor engagement and protracted timelines – driving up costs…
All articles by Alexander Love
Alexander Love
-
-
Peptide drug conjugates: How the Indena and Chemi partnership is delivering
The pharmaceutical industry is investing heavily in therapies capable of delivering high-potent treatments to diseased cells while limiting damage to…
-
Enhance clinical trial screening and improve patient matching accuracy
Traditional approaches to patient-trial matching often rely solely on structured data, leading to inaccurate eligibility lists and missed opportunities to…
-
How price variation impacts employers
This is the first episode in our second season exploring the evolving landscape of real-world data and its role in…
-
Quality by design: The impact of disconnected systems on clinical data
As clinical trials become more digitalised, the data landscape is expanding faster than the processes designed to control it. Electronic…
-
Podcast: The growth of clinical trials and research in Israel
Israel has a robust and growing clinical trials ecosystem. This podcast explores the factors that what make Israel such an…
-
The cost of inefficiencies in clinical trials
Clinical trials are expensive, time-sensitive, and closely monitored, with sponsors and contract research organisations (CROs) under pressure to run studies…
-
How Saudi Arabia is developing as a Middle East hub for clinical trials
Saudi Arabia is primed to emerge as the Middle East’s key hub for clinical trials, driven by both sustained state…
-
How eSource adoption is saving time and costs in clinical research
Clinical trial sites and sponsors are turning to eSource to ease pressures over costs and unlock efficiencies, with a recent…
-
The strategic investments expanding CDMO capabilities for HPAPIs and ADCs
As oncology pipelines continue to expand and targeted therapies become more sophisticated, contract development and manufacturing organisations (CDMOs) must invest…